GSK RSV vaccine achieves blockbuster status in just over six months

GSK PLC has seen its RSV vaccines shoot to blockbuster status in little over six months, according to the Financial Times citing analysts.

The term blockbuster refers to any drug with annual sales of more than US$1 billion, a landmark likely to have been passed by Arexvy inoculation in the final quarter of last year.